Login to Your Account



Alzheimer's Guidance Shows Challenges Facing FDA, Industry

By Mari Serebrov
Washington Editor

Monday, April 1, 2013
Much to-do has been made about the FDA's draft guidance on developing drugs for early stage Alzheimer's disease (AD), but some people are missing the point, especially if they think the agency is "loosening" its standards for Alzheimer's treatments, according to an FDA official.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription